Many Americans are taking GLP1 medications, which include weight loss and diabetes medications Ozempic and Wegovy.

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Come May 22, compounding pharmacies must stop making semaglutide injections, which serve as a more affordable generic ...

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Compounding pharmacies will no longer be allowed to create semaglutide injections, a generic and cheaper version of Ozempic and Wegovy. This comes after a judge rejected a bid by these pharmacies to ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

A Howard County man is suing Novo Nordisk, alleging Ozempic caused him to go blind after using the drug to treat diabetes. He seeks damages in court.